Mazdutide vs Semaglutide
A side-by-side research comparison of Mazdutide and Semaglutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Mazdutide | Semaglutide |
|---|---|---|
| Full name | Mazdutide (Dual GLP-1/Glucagon Agonist) | Semaglutide (GLP-1 Receptor Agonist) |
| Category | Weight Management | Weight Management |
| Status | Phase 3 Clinical Trial | FDA Approved |
| Mechanism | Dual activation of GLP-1 receptors for appetite suppression combined with glucagon receptor activation for enhanced hepatic lipid oxidation and energy expenditure. | Binds GLP-1 receptors in the pancreas to stimulate insulin secretion, in the brain to reduce appetite, and in the GI tract to slow gastric emptying. 94% homology to native GLP-1. |
| Molecular weight | 4,300 Da (approximate) | 4,114 Da |
| Half-life | 5-7 days | 7 days (168 hours) |
| Bioavailability | High (SubQ) | High (SubQ ~89%), Moderate (oral ~1% with SNAC) |
| Typical dose | 3-9 mg | 0.25 mg → titrate up to 2.4 mg |
| Frequency | Once weekly | Once weekly |
| Route | Subcutaneous | Subcutaneous injection |
Mazdutide reported benefits
- Significant weight loss (up to 18%)
- Liver fat reduction
- Improved insulin sensitivity
- Once-weekly convenience
- Potential MASH benefit
Semaglutide reported benefits
- Significant weight loss (15-17%)
- Improved glycemic control
- Cardiovascular risk reduction
- Reduced food cravings
- Lower HbA1c
Related comparisons
Research and educational reference only. Not medical advice.